Efficacy of Focused Shock Waves Combined With Adjuvant Therapy With Tendon Supplement

Sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari (Other)
Overall Status
Completed
CT.gov ID
NCT04664712
Collaborator
(none)
44
1
2
14.3
3.1

Study Details

Study Description

Brief Summary

Physical treatment with focused shock waves is effective in the treatment of tendonitis. Food supplements could facilitate the healing of tendinopathies when combined with shock wave therapy.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Tendisulfur Pro
  • Device: Focused shock wave
N/A

Detailed Description

A single-blind, randomized prospective study (level of evidence IB) was designed. Patients with plantar fasciitis were recruited and randomized to group A and group B. Group A was treated with focused shock waves alone and group B with a combination of focused shock waves and tendon supplement. Pain remission (primary endpoint) and functional recovery (secondary endpoint) are monitored in both groups at three time points (Months 0, 3, and 6).

Study Design

Study Type:
Interventional
Actual Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy of Focused Shock Waves Combined With Adjuvant Therapy With Tendon Supplement in the Treatment of Plantar Fasciitis: a Prospective Randomized Study
Actual Study Start Date :
Sep 11, 2019
Actual Primary Completion Date :
May 1, 2020
Actual Study Completion Date :
Nov 20, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: shock wave

Device: Focused shock wave
We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.

Active Comparator: shock wave and tendon supplement

Dietary Supplement: Tendisulfur Pro
Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) [17, 18], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)

Device: Focused shock wave
We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.

Outcome Measures

Primary Outcome Measures

  1. Change in Visual Analogue Score (VAS) [T0 (recruitment); T1 (three months)]

    The pain was quantified using the VAS scale with the scores ranging between 0 (no pain) and 10 (worst imaginable pain).

  2. Change in Visual Analogue Score (VAS) [T1 (three months); T2 (six months)]

    The pain was quantified using the VAS scale with the scores ranging between 0 (no pain)

Secondary Outcome Measures

  1. Change in American Foot & Ankle Score (AOFAS) [T0 (recruitment); T2 (six months)]

    The scores ranging between 100 (no disability) and 0 (maximum disability)

  2. Change in Foot Function Index (FFI) [T0 (recruitment); T2 (six months)]

    The scores ranging between 100 (no disability) and 0 (maximum disability).

  3. Roles & Maudsley (R&M) [T1 (three months)]

    Monitorization of the patient's perception of improvement, with the scores ranging from 1 (excellent) to 4 (minimum).

  4. Roles & Maudsley (R&M) [T2 (six months)]

    Monitorization of the patient's perception of improvement, with the scores ranging from 1 (excellent) to 4 (minimum).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • plantar heel pain diagnosed clinically and instrumentally (ultrasound) as plantar fasciitis, that has not responded to conservative treatment for at least six months;
Exclusion Criteria:
  • History of previous fractures or ankle and heel surgery;

  • Recurrence of previous local painful episodes;

  • Lesion of the plantar fascia on US examination;

  • Presence of pathologies that affect the function of the foot (lumbar radiculopathy, Achilles tendinitis, Morton's neuroma, etc.);

  • Chronic inflammatory conditions such as psoriasis, psoriatic arthritis, spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis, chronic inflammatory bowel disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 AOUC Policlinico di Bari - UOC Ortopedia e Traumatologia Bari Italy 70124

Sponsors and Collaborators

  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Investigators

  • Principal Investigator: Biagio Moretti, Prof, University of Bari Aldo Moro

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
ClinicalTrials.gov Identifier:
NCT04664712
Other Study ID Numbers:
  • ESWT-TP
First Posted:
Dec 11, 2020
Last Update Posted:
Dec 11, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 11, 2020